Open AccessRepurposing Nucleoside Analogs for Human Coronaviruses
Author(s) -
Keivan Zandi,
Franck Amblard,
Katie Musall,
Jessica Downs-Bowen,
Ruby Kleinbard,
Adrian Oo,
Dong Cao,
Bo Liang,
Olivia Russell,
Tamara R. McBrayer,
Leda Bassit,
Baek Kim,
Raymond F. Schinazi
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01652-20
Subject(s) - nucleoside , coronavirus , virology , repurposing , nucleoside analogue , covid-19 , betacoronavirus , nucleoside triphosphate , medicine , biology , pharmacology , nucleotide , disease , infectious disease (medical specialty) , biochemistry , gene , ecology
Coronavirus disease 2019 (COVID-19) is a serious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or CoV-2). Some reports claimed certain nucleoside analogs to be active against CoV-2 and thus needed confirmation. Here, we evaluated a panel of compounds and identified novel nucleoside analogs with antiviral activity against CoV-2 and HCoV-OC43 while ruling out others. Of significance, sofosbuvir demonstrated no antiviral effect against CoV-2, and its triphosphate did not inhibit CoV-2 RNA polymerase.